Treatment of SCID mice bearing human breast cancer xenografts with SP90-LD.

<p><b>a</b>, Mice bearing BT483-derived breast cancer xenografts with average tumor size of ∼75 mm³ were treated with 3 mg/kg at weekly intervals (for a total of three injections) of either FD, LD, SP90-LD, or an equal volume of PBS by intravenous injection. <i>n</i> = 6 each group. Points, mean tumor volumes. <b>b</b>, Mice bearing size-matched BT483-derived breast cancer xenografts with tumor size of ∼500 mm³ were treated with SP90-LD, LD, or FD, for a total doxorubicin dosage of 9 mg/kg (3 mg/kg/injection, twice a week). <i>n</i> = 8. The average tumor volumes at cessation of treatment in the LD, FD and control PBS groups were 1.5, 6.2 and 8.4 times larger than that in the SP90-LD-treated group, respectively. <b>c</b>, Mice bearing orthotopic breast cancer tumors with average tumor size of ∼500 mm³, MCF-7-Luc, were injected with either SP90-LD, FD or LD, for a total doxorubicin dosage of 9 mg/kg (3 mg/kg/injection, twice a week). The tumors were imaged and luminescence was quantified at the indicated days by IVIS200. <i>n</i> = 5. <b>d</b>, Volume of tumors depicted in (c). Error bar, s.d.; *<i>P</i><0.05; **<i>P</i><0.01; ***<i>P</i><0.001.